IntegraGen S.A.. (3/8/17). "Press Release: Laboratoire Cerba Enters into Licensing Agreement with IntegraGen for the Commercialization of miR-31-3p Tumor Expression Test in France, Benelux, Middle East and Africa". Saint-Ouen l’Aumône & Évry.

	Region	France
	Organisation	IntegraGen S.A. (Paris: ALINT)
	Group	OncoDNA (Group)
	Organisation 2	Laboratoire Cerba
	Group	Cerba (Group)
	Product	miR-31-3p biomarker
	Product 2	pharmacogenomic/pharmacogenetic cancer test
	Index term	Cerba–IntegraGen: molecular diagnostics, 201703– license €na to commercialise miR-31-3p tumor expression test in FR + Benelux + MENA
	Person	Cado, Sylvie (Laboratoire Cerba 201703 CEO)
	Person 2	Courtieu, Bernard (IntegraGen 201203 CEO)

IntegraGen SA (Paris:ALINT), a company specializing in the decoding of the human genome and performing interpretable genomic tests for academic and private laboratories and a developer of diagnostic tools in oncology, and Laboratoire CERBA, the European leader in specialized clinical pathology, serving more than 50 countries in Europe, Africa and Asia, announced today the signing of a licensing agreement allowing Laboratoire CERBA to develop and provide to prescribing clinicians a test based on IntegraGen’s proprietary miR-31-3p biomarker. Laboratoire CERBA will develop this test to complement its existing portfolio and further enable physicians to proactively identify metastatic colorectal cancer patients who will have increased benefit from treatment with anti-EGFR therapy. Financial details and terms of the agreement were not disclosed.

“Laboratoire CERBA has a longstanding history of providing innovative & clinically relevant tests to clinicians and patients, and it is a natural expansion of our testing portfolio to include miR-31-3p to our portfolio of tests. With this licensing agreement we remain at the forefront of precision medicine and are able to provide oncologists genomic information that will allow them to choose the optimal therapy for patients with metastatic colorectal cancer, a disease that affects more than 170,000 patients in the EU,” declared Sylvie Cado, CEO of Laboratoire CERBA. “We look forward to making this test available for clinicians in the first half of 2017 once we have completed the validation steps in our laboratory.”

“This new partnership with Laboratoire CERBA is a significant achievement for IntegraGen since it is a major step for the company’s diagnostics activities,” added Bernard Courtieu, IntegraGen’s CEO. “With the launch of our first proprietary test in Europe, it also represents the culmination of more than five years of research and development efforts, from the early stages of biomarker discovery to the availability of a miR-31-3p expression test for oncologists and patients. IntegraGen today delivers a big step in the field of personalized medicine since this test represents a major improvement for treating patients with metastatic colorectal cancer.”

About IntegraGen

IntegraGen is a company specializing in deciphering the human genome and producing relevant and easily interpretable data for academic and private laboratories. IntegraGen’s oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients. As of December 31, 2016, IntegraGen had 38 employees and had generated revenue of €6.0 million in 2016. Based in Evry Genopole, IntegraGen also has an U.S. office in Cambridge, Massachusetts. IntegraGen is listed on Alternext of Euronext Paris (ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).

www.integragen.com

About Laboratoire CERBA

Created in 1967 and accredited in compliance with the NF ISO 15189 standard since 1999, Laboratoire CERBA is the European leader in specialized clinical pathology. Integrating more than 40 medical specialties and employing over 600 highly qualified staff on a single site located to the north-west of Paris, on average Laboratoire CERBA handles some 40,000 dossiers daily.

With a state-of-the-art technological platform, it is able to offer private and hospital laboratories in over 50 countries a wide range of specialized clinical pathology tests in fields such as molecular biology, oncology, allergology, toxicology, hormonology, and infectious and metabolic diseases together with diagnostic analyses for genetic diseases in cytogenetics and molecular genomics.

Laboratoire CERBA ceaselessly works to develop its technological and human potential and has launched numerous collaborative projects with both public and private establishments to ensure it always remains on the leading-edge of innovation. Since 1998, Laboratoire CERBA's pathologists have contributed to over 500 scientific publications.

It is also a founder member of the CERBA HEALTHCARE group, an international clinical pathology group, working in three complementary sectors:

> routine clinical pathology mainly in France, Belgium and Luxembourg with over 300 laboratories, 150 sample collection centers and 50 technical platforms;
> specialized clinical pathology with the CERBA platform;
> clinical pathology for trial trials, essential to the pharmaceutical and biotechnology industry for the development of new molecules, through its subsidiary BARC today present on five continents.

Recently the Group has diversified into the veterinary clinical pathology sector with the creation of a dedicated unit, CERBA VET.

It now employs nearly 4,300 staff, including 400 pathologists.

www.lab-cerba.com

www.cerbahealthcare.com

Contacts

IntegraGen
Bernard COURTIEU / Laurence RIOT LAMOTTE
President and CEO / Chief Financial Officer
contact@integragen.com
Tel: +33 (0)1 60 91 09 00
or
NewCap
Investors relations
Emmanuel HUYNH
Louis-Victor DELOUVRIER
integragen@newcap.eu
Tel: +33 (0)1 44 71 98 53
or
Laboratoire CERBA
Pascale LAURENT
Director of Communication and Marketing
pascale.laurent@cerbahealthcare.com

Record changed: 2023-06-05